Abbott (ABT) and Sekisui announced an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots.
As per the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.
Coagulation testing helps clinicians in assessing people before many medical treatments and in monitoring those who take medications that can affect clotting. It is also useful in the diagnosis of blood-related disorders, such as hemophilia and thrombosis.
For comments and feedback: editorial@rttnews.com